Director of Invivyd, Inc. Sells $30,718.73 in Company Stock

On December 16th, 2023, Terrance Mcguire, a director at Invivyd, Inc. (NASDAQ:IVVD), sold a total of 65,359 shares of the company's stock. The shares were sold at an average price of $0.47, amounting to a total value of $30,718.73. After this transaction, Mcguire's direct ownership in the company stands at 4,012,320 shares, which are currently valued at approximately $1,885,790.40. This sale represents a 1.60% decrease in his holding.

The details regarding this sale were disclosed in a filing with the Securities and Exchange Commission.

Recent Stock Transactions by Mcguire

In addition to the recent sale, Terrance Mcguire made other significant stock transactions in December. On December 11th, he sold 160,400 shares at an average price of $0.59, totaling $94,636.00. Furthermore, on December 9th, Mcguire sold 150,000 shares at an average price of $0.61, amounting to $91,500.00.

Market Performance of Invivyd Stock

On the same day of the transaction, Invivyd's stock experienced a 17.6% drop, trading down $0.10 to reach a price of $0.45. The trading volume was reported at 1,228,420 shares, which is higher than the average volume of 651,886. As of now, the company has a market capitalization of approximately $53.89 million, with a P/E ratio of -0.23.

Analyst Ratings and Price Targets

Multiple research firms have recently updated their price targets for Invivyd. Morgan Stanley lowered its target price from $9.50 to $3.55, recommending an 'overweight' rating on November 20th. Similarly, HC Wainwright decreased its price objective from $15.00 to $10.00 while maintaining a 'buy' rating. EF Hutton Acquisition Co. I also raised Invivyd to a 'strong-buy' rating in a report released on October 30th. Currently, the stock holds a consensus rating of 'Buy' with an average target price of $7.89, as reported by MarketBeat.com.

Recent Institutional Investments

Several institutional investors have also adjusted their holdings in Invivyd. State Street Corp increased its stake by 3.7% in the third quarter, now owning 1,018,640 shares valued at $1,039,000. Marshall Wace LLP has also raised its position by 4.2%, currently holding 786,899 shares worth $866,000. Additionally, Acadian Asset Management LLC significantly increased its stake by 232%, taking ownership of 678,706 shares valued at approximately $745,000. As it stands, institutional investors hold 70.36% of the company's stock.

About Invivyd, Inc.

Invivyd, Inc. is a commercial-stage biopharmaceutical company specializing in developing and commercializing antibody-based solutions for infectious diseases in the United States. The company operates the INVYMAB platform, which integrates viral surveillance and predictive modeling with advanced antibody engineering.

Final Thoughts

Investors may want to consider the recent actions by the company's director alongside market analysts’ insights when evaluating the potential of Invivyd stock.

Invivyd, Stock, Director